Table 2 represents recent FDA approvals along with respective clinical trials for ibrutinib, acalabrutinib and zanubrutinib. A recent publication from Zao et al. highlighted the effects of zanubrutinib treatment on immune cell re-modulation. Data from 25 R/R CLL/SLL showed that zanubrutinib treatment, like ibrutinib, led to reduction of PD-1 expression on CD4+ and CD8+ T-cells, PD-L1 on CLL cells, and inhibited suppressor cell functions [103]. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.